Biggest Manufacturer，Acalabrutinib（1420477-60-6） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Acalabrutinib, CAS#1420477-60-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 13KG in stock, pls check:

Name:Acalabrutinib

CAS#: 1420477-60-6

Formula: C26H23N7O2 
Exact Mass: 465.19132 
Molecular Weight: 465.52 
Elemental Analysis: C, 67.08; H, 4.98; N, 21.06; O, 6.87

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Acalabrutinib Intermediates:

1. Acalabrutinib Intermediate:(3-chloropyrazin-2-yl)methanamine dihydrochloride

Cas#867165-53-5

We have more than 23kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Acalabrutinib Intermediate:(S)-benzyl-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate

Cas#1420478-87-0

We have more than 33kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3. Acalabrutinib Intermediate:(S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine
-1-carboxylate

Cas#1420478-88-1

We have more than 16kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4. Acalabrutinib Intermediate:4-(pyridin-2-yl-aminocarbonyl)benzeneboronic acid

Cas#850568-25-1

We have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5. Acalabrutinib Intermediate:N-Pyridin-2-yl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide

Cas#1383385-64-5

We have more than 23 kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Maly J, Blachly JS. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Curr Hematol Malig Rep. 2016 Feb 11. [Epub ahead of print] PubMed PMID: 26893063.

2: Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. PubMed PMID: 26641137.

Biggest Manufacturer， Venetoclax ABT-199（1257044-40-8） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

 2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

Firts Time open Synthesis route, we use the best way, improve the yield 30%， now each Intermediates, we could supply more than 100kg. All from GMP plant.
Welcome to Site audit.

1.

 Venetoclax ABT-199, CAS#1257044-40-8, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than34 KG in stock, pls check:

Name:Venetoclax ABT-199

CAS#: 1257044-40-8

Formula: C45H50ClN7O7S 

Exact Mass: 867.3181 
Molecular Weight: 868.44 
Elemental Analysis: C, 62.24; H, 5.80; Cl, 4.08; N, 11.29; O, 12.90; S, 3.69

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Venetoclax ABT-199 Intermediates:

1.Venetoclax ABT-199 Intermediate:1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine 

Cas#1228780-72-0 

We have more than 43kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Venetoclax ABT-199 Intermediate:1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine 

Cas#1628047-87-9

We have more than 36kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.Venetoclax ABT-199 Intermediate:Methyl 2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-4-fluorobenzoate 

Cas#1235865-75-4

We have more than 32kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4.Venetoclax ABT-199 Intermediate:3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide

Cas#1228779-96-1

We have more than 45kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Seymour J. ABT-199 for Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700. PubMed PMID: 25658896.

2: Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015 Jan 15;6:e1593. doi: 10.1038/cddis.2014.525. PubMed PMID: 25590803.

3: Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jan 12. doi: 10.1111/bjh.13278. [Epub ahead of print] PubMed PMID: 25582069.

4: Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leuk Lymphoma. 2015 Jan 28:1-7. [Epub ahead of print] PubMed PMID: 25373508.

5: Ko TK, Chuah CT, Huang JW, Ng KP, Ong ST. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget. 2014 Oct 15;5(19):9033-8. PubMed PMID: 25333252; PubMed Central PMCID: PMC4253416.

6: Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9. PubMed PMID: 25301704.

7: Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015 Mar;168(5):765-8. doi: 10.1111/bjh.13149. Epub 2014 Oct 4. PubMed PMID: 25284608.

8: ABT-199 shows effectiveness in CLL. Cancer Discov. 2014 Sep;4(9):OF7. doi: 10.1158/2159-8290.CD-NB2014-102. Epub 2014 Jul 3. PubMed PMID: 25185206.

9: Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep;4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353. Epub 2014 Jul 3. PubMed PMID: 24994123; PubMed Central PMCID: PMC4154982.

10: Wei A. ABT-199 partners with azacitidine to contest myeloid malignancies. Leuk Lymphoma. 2015 Jan;56(1):8-9. doi: 10.3109/10428194.2014.919638. Epub 2014 Jul 15. PubMed PMID: 24794804.

Biggest Manufacturer，Avibactam（1192491-61-4） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

                        2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Avibactam, CAS#1192491-61-4, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:

Name:Avibactam

CAS#: 1192491-61-4

Formula: C7H10N3NaO6S 
Exact Mass: 
Molecular Weight: 287.22 
Elemental Analysis: C, 29.27; H, 3.51; N, 14.63; Na, 8.00; O, 33.42; S, 11.16

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Avibactam Intermediates:

1. Avibactam Intermediate:(2S,5R)-Methyl-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate (1:1)
Cas#1416134-48-9
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Avibactam Intermediate:(2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxamide
Cas#1416134-49-0
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Rereference：

1: Krishnan NP, Nguyen NQ, Papp-Wallace KM, Bonomo RA, van den Akker F. Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS One. 2015 Sep 4;10(9):e0136813. doi: 10.1371/journal.pone.0136813. eCollection 2015. PubMed PMID: 26340563.
2: Caravaca-Fontán F, Jiménez-Álvaro S, Marcén-Letosa R, Fernández-Rodríguez A, Rodríguez-Navarro CQ. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation. Nefrologia. 2015 Jul 22. pii: S0211-6995(15)00070-3. doi: 10.1016/j.nefro.2015.01.001. [Epub ahead of print] English, Spanish. PubMed PMID: 26306955.
3: Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622. PubMed PMID: 26289307; PubMed Central PMCID: PMC4545577.
4: Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.01165-15. [Epub ahead of print] PubMed PMID: 26195508.
5: Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH. Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae. Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7. doi: 10.1128/AAC.00548-15. Epub 2015 Jul 13. PubMed PMID: 26169413.
6: Sillén H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R, Glendining K. Determination of avibactam and ceftazidime in human plasma samples by LC-MS. Bioanalysis. 2015 Jul;7(12):1423-34. doi: 10.4155/bio.15.76. PubMed PMID: 26168250.
7: Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis. 2015 Jun 17. pii: S0732-8893(15)00211-4. doi: 10.1016/j.diagmicrobio.2015.06.008. [Epub ahead of print] PubMed PMID: 26162518.
8: Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015 Sep;24(9):1261-73. doi: 10.1517/13543784.2015.1062873. Epub 2015 Jul 6. PubMed PMID: 26145447.
9: Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14. Review. PubMed PMID: 26143591.
10: Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015 Jul 1. pii: dkv170. [Epub ahead of print] PubMed PMID: 26133566.
11: Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase. Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22. PubMed PMID: 26100712.
12: Tominaga N, Edeki T, Li J, Learoyd M, Bouw MR, Das S. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015 Aug;21(8):551-8. doi: 10.1016/j.jiac.2015.04.006. Epub 2015 Apr 28. PubMed PMID: 26076867.
13: Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29. PubMed PMID: 26024868.
14: Jones RN, Holliday NM, Krause KM. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination. Antimicrob Agents Chemother. 2015 Aug;59(8):5036-9. doi: 10.1128/AAC.00021-15. Epub 2015 May 26. PubMed PMID: 26014937; PubMed Central PMCID: PMC4505265.
15: Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic. Med Lett Drugs Ther. 2015 May 25;57(1469):79-80. PubMed PMID: 25989198.
16: Rashid MU, Rosenborg S, Panagiotidis G, Söderberg-Löfdal K, Weintraub A, Nord CE. Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota. Antimicrob Agents Chemother. 2015 Aug;59(8):4504-9. doi: 10.1128/AAC.00530-15. Epub 2015 May 18. PubMed PMID: 25987638; PubMed Central PMCID: PMC4505277.
17: Rashid MU, Rosenborg S, Panagiotidis G, Löfdal KS, Weintraub A, Nord CE. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents. 2015 Jul;46(1):60-5. doi: 10.1016/j.ijantimicag.2015.02.027. Epub 2015 Apr 20. PubMed PMID: 25979639.
18: Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11. PubMed PMID: 25963984; PubMed Central PMCID: PMC4468705.
19: Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother. 2015 Aug;70(8):2279-86. doi: 10.1093/jac/dkv094. Epub 2015 May 8. PubMed PMID: 25957381; PubMed Central PMCID: PMC4500773.
20: Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14. PubMed PMID: 25956844.

Biggest Manufacturer，Ribociclib (Lee011)（1374639-75-4） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

 2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Ribociclib (Lee011), CAS#1374639-75-4, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:

Name:Ribociclib (Lee011)

CAS#: 1374639-75-4

Formula: C27H36N8O5 
Exact Mass: 
Molecular Weight: 552.636 
Elemental Analysis: C, 58.68; H, 6.57; N, 20.28; O, 14.48

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Ribociclib (Lee011) Intermediates:

1. Ribociclib (Lee011) Intermediate:4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester

Cas#571188-59-5,

We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Ribociclib (Lee011) Intermediate:5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine

Cas#733039-20-8,

We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3. Ribociclib (Lee011) Intermediate:(2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol

Cas#1374639-77-6

We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4. Ribociclib (Lee011) Intermediate:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
Cas#1211443-61-6

We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. PubMed PMID: 27717303.
2: Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. PubMed PMID: 27336726.
3: Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. PubMed PMID: 27542767.
4: Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Review. PubMed PMID: 27493615; PubMed Central PMCID: PMC4960359.
5: Ribociclib Lengthens Breast Cancer Survival. Cancer Discov. 2016 Dec;6(12):1299. PubMed PMID: 27810861.
6: Aristizabal Prada ET, Noelting S, Spoettl G, Maurer J, Auernhammer CJ. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology. 2017 Feb 23. doi: 10.1159/000463386. [Epub ahead of print] PubMed PMID: 28226315.
7: de Gramont A, Herrera A, de Gramont A. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288-289. PubMed PMID: 28102649.
8: Araki K, Miyoshi Y. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288. PubMed PMID: 28102647.
9: Hortobagyi GN. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):289. doi: 10.1056/NEJMc1615255. PubMed PMID: 28099830.
10: Burki TK. Ribociclib in HR-positive, HER2-negative breast cancer. Lancet Oncol. 2016 Nov;17(11):e482. doi: 10.1016/S1470-2045(16)30502-2. PubMed PMID: 27746106.
11: Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, Wei W, Dugger TC, Knudsen E, Arteaga CL. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017 Mar 1. pii: canres.2653.2016. doi: 10.1158/0008-5472.CAN-16-2653. [Epub ahead of print] PubMed PMID: 28249908.
12: Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V. [Cell cycle inhibitors in endocrine receptor positive breast cancer]. Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. French. PubMed PMID: 28126188.
13: Wood A, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King F, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris J, Mosse YP. Dual ALK and CDK4/6 inhibition demonstrates on-target synergy against neuroblastoma. Clin Cancer Res. 2016 Dec 16. pii: clincanres.1114.2016. [Epub ahead of print] PubMed PMID: 27986745.
14: Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin Cancer Res. 2016 Oct 11. doi: 10.1158/1078-0432.CCR-16-1131. [Epub ahead of print] PubMed PMID: 27729458.
15: Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015 Dec 18;10(12):2680-6. doi: 10.1021/acschembio.5b00368. PubMed PMID: 26390342; PubMed Central PMCID: PMC4684772.
16: O'Sullivan CC. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opin Pharmacother. 2016 Aug;17(12):1657-67. doi: 10.1080/14656566.2016.1201072. Review. PubMed PMID: 27322766.
17: Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb;16(1):8-17. doi: 10.1016/j.clbc.2015.07.005. Review. PubMed PMID: 26303211.
18: Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Review. PubMed PMID: 27017286.
19: Konecny GE. Cyclin-dependent kinase pathways as targets for women's cancer treatment. Curr Opin Obstet Gynecol. 2016 Feb;28(1):42-8. doi: 10.1097/GCO.0000000000000243. Review. PubMed PMID: 26642065.

20: Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5231-6. doi: 10.1073/pnas.1424313112. PubMed PMID: 25848011; PubMed Central PMCID: PMC4413320.